A Patient’s Perspective on Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines
Paul Morris – 6 February 2022
Glomerular filtration rate early after liver transplantation independently predicts atherosclerotic events
Ramzi Hassouneh, Samarth Patel, Steve Shen, Anh Bui, Taseen Syed, Sean Flynn, Vaishali Patel, Mark D. Muthiah, Amit Sharma, Chandra Bhati, Mohammad Shadab Siddiqui – 5 February 2022 – Cardiovascular disease (CVD) is an important cause of mortality among liver transplantation (LT) recipients; however, the data on CVD risk stratification following LT are limited. Thus, the primary aim of this study was to evaluate the association between decline in renal function early after LT and atherosclerotic events. This retrospective study included all patients receiving LT between 2007 and 2019.
The HEPHAISTOS Trial and Mammalian Target of Rapamycin Inhibitors in Liver Transplantation—Hiding in Plain Sight
Greg J. McKenna – 5 February 2022
Core implementation strategies for improving cirrhosis care in the Veterans Health Administration
Vera Yakovchenko, Timothy R. Morgan, Edward J. Miech, Brittney Neely, Carolyn Lamorte, Sandra Gibson, Lauren A. Beste, Heather McCurdy, Dawn Scott, Rachel I. Gonzalez, Angela M. Park, Byron J. Powell, Jasmohan S. Bajaj, Jason A. Dominitz, Maggie Chartier, David B. Ross, Matthew J. Chinman, Shari S. Rogal – 5 February 2022
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?
Vatche G. Agopian, Ju Dong Yang, Yazhen Zhu, Sungyong You, Hsian‐Rong Tseng – 5 February 2022
ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?
Mazen Noureddin, Manal F. Abdelmalek – 5 February 2022
Measure twice, cut once
Sean Koppe – 4 February 2022
Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992–2018
Christian S. Alvarez, Jessica L. Petrick, Dominick Parisi, Brian J. McMahon, Barry I. Graubard, Katherine A. McGlynn – 4 February 2022
Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population‐Based Study in Germany
Yvonne Huber, Andreas Schulz, Irene Schmidtmann, Manfred Beutel, Norbert Pfeiffer, Thomas Münzel, Peter R. Galle, Philipp S. Wild, Karl J. Lackner, Jörn M. Schattenberg – 4 February 2022 – The prevalence of liver disease, and especially of advanced liver fibrosis, in the German population is poorly defined. The aim of the study was to explore liver enzymes and surrogate scores of hepatic steatosis and advanced hepatic fibrosis in a population‐based cohort study in Germany.
Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992–2018
Christian S. Alvarez, Jessica L. Petrick, Dominick Parisi, Brian J. McMahon, Barry I. Graubard, Katherine A. McGlynn – 4 February 2022